Anti-Human CD119 (IFN-γ Rα Chain) – Purified in vivo GOLD™ Functional Grade

The clone GIR-208 is a mouse antibody used to target the human interferon-gamma receptor alpha-chain (CD119). However, it is not typically used in studies involving the mouse interferon-gamma receptor directly because it is specific for human CD119.

In in vivo mouse studies, GIR-208 is often used as an isotype control rather than a specific therapeutic or diagnostic agent. This is because it does not interact with mouse interferon-gamma receptors but can serve as a control to assess the specificity of other treatments or antibodies in mouse models. For example, in studies involving the blockade of type I interferon signaling, GIR-208 has been used as an isotype control to ensure that observed effects are not due to non-specific actions of the antibody treatment.

Thus, while GIR-208 antibodies are not used to target mouse biological processes directly, they can be valuable tools in experimental designs requiring appropriate controls.

Here is a summary of how GIR-208 is used in mouse studies:

• Isotype Control: Used to account for non-specific effects in studies involving mouse models.
• Species Reactivity: Specific for human CD119, not reactive with mouse interferon-gamma receptors.
• Function: Does not block mouse interferon-gamma receptors but serves as a control to validate experimental results.

The correct storage temperature for a sterile packaged clone such as GIR-208 is typically between 2°C and 8°C (36°F and 46°F), refrigerated and protected from light.

This recommendation aligns with standard practices for storing sterile antibodies and biological products, such as those described for anti-human CD119 (IFN-? R ? chain) antibodies from BioLegend, which specify keeping the solution undiluted and refrigerated between 2°C and 8°C, never frozen, and avoiding prolonged light exposure.

If GIR-208 were a cell line or a biological reagent other than an antibody, very low temperatures (such as ?80°C or in liquid nitrogen) could be required; however, for most sterile packaged clones and antibodies intended for immediate laboratory use, 2°C to 8°C is the industry standard unless stated otherwise by the manufacturer. Always check the package insert or supplier’s datasheet for any clone-specific guidance.

Summary of Key Practices:

• Refrigerate at 2°C–8°C
• Do not freeze
• Protect from light
• Follow manufacturer’s instructions for particular products, if available

If the clone GIR-208 is a type of sterile antibody or reagent like those referenced, these guidelines should apply unless otherwise noted in its documentation.

Commonly used antibodies or proteins with GIR-208 in the literature include other monoclonal antibodies against components of the interferon-gamma (IFN-?) signaling pathway, particularly GIR-301 and isotype control antibodies such as MOPC-21.

Essential context and details:

• GIR-301 is the antibody most often used in parallel with GIR-208. Both are murine monoclonal antibodies generated against the human IFN-? receptor (IFNGR1). They fully block binding of radiolabeled IFN-? to human cells, recognize similar or overlapping epitopes, and are used interchangeably to inhibit IFN-? responses in cellular assays.
• Additional monoclonal antibodies targeting different epitopes of IFNGR1 (e.g., GIR-72, GIR-76, and GIR-94) have also been described, though their blocking activity is more moderate compared to GIR-208 and GIR-301.
• Isotype-matched control antibodies (such as MOPC-21, mouse IgG1) are regularly used as negative controls in experiments to ensure specificity of GIR-208–mediated effects.
• In broader studies on interferon signaling, antibodies against other interferons (IFN-? and IFN-?), their receptors (IFNAR2), as well as neutralizing antibodies against IFN-? itself (for example, clone NIB42), may be used for comparative or mechanistic experiments with GIR-208.

Summary of commonly used antibodies/proteins alongside GIR-208:

No direct literature indicates the use of unique detection antibodies or epitope tags specifically with GIR-208; instead, experiments often focus on comparing influence on IFN-? receptor function using other monoclonal antibodies (like GIR-301) and appropriate controls.

Overview

Clone GIR-208 is an isotype control antibody used in experimental immunology, particularly in studies of interferon signaling pathways. The primary scientific citation for GIR-208 in the provided literature is from a study on the role of type I interferon (IFN) signaling during viral infection in mice.

Key Findings from the GIR-208 Citation

• Control Role: GIR-208 was used as a negative control antibody targeting human interferon-gamma receptor subunit 1 (IFNGR1) in experiments designed to investigate the effects of blocking type I interferon receptor (IFNAR1) signaling with another antibody, MAR1-5A3. Importantly, GIR-208 does not block interferon signaling in mice; it serves to rule out non-specific or off-target effects of antibody treatment.
• Experimental Design: Adult C57BL/6J mice were inoculated with the virus D2Y98P. Some were treated with MAR1-5A3 (which blocks IFNAR1), some with GIR-208 (isotype control), and others were genetic knockouts for Ifnar1.
• Clinical Outcomes: Mice treated with GIR-208 showed no weight loss, no signs of illness, and all survived until the end of the experiment (15 days post-infection, dpi), identical to untreated wild-type controls. This suggests GIR-208 did not interfere with the mice’s ability to control the viral infection.
• Serological Results: Sera from GIR-208-treated mice exhibited no virus-neutralizing activity by focus reduction neutralization test (FRNT) at 15 dpi, confirming the mice were not productively infected (i.e., did not mount an adaptive immune response to the virus).
• Contrast with Experimental Group: In contrast, MAR1-5A3-treated mice (blocking IFNAR1) showed substantial neutralizing antibody titres, indicating viral replication and immune activation occurred in these animals.
• Control Validation: The findings reinforced that the disease phenotype and high mortality seen in Ifnar1-deficient mice are not recapitulated by antibody-mediated blockade in wild-type mice, highlighting the importance of genetic versus pharmacologic modulation of the interferon pathway.

Summary Table

Conclusion

GIR-208 is primarily documented in the literature as a critical experimental control for studies on interferon signaling, confirming that observed phenotypes are specifically due to the blockade of the intended pathway (IFNAR1) and not to non-specific antibody effects. The clone itself does not have inherent biological activity in the context of these mouse infection models but is essential for validating the specificity of experimental interventions.